* Professor of Physiology (tenure), College of Medicine, University of Arizona
* Professor of Psychology, College of Medicine, University of Arizona
* Professor, Evelyn F. McKnight Brain Institute, University of Arizona
* Professor, Bio5 Institute, University of Arizona
* Sarver Heart Center
* CEO,Founder, ProNeurogen, Inc, www.proneurogen.com

Dr. Meredith Hay is a Professor of Physiology at the University of Arizona College of Medicine and Founder and CEO of ProNeurogen, Inc. Dr. Hay is Past-President of the American Physiological Society and the former Executive Vice President and Provost of The University of Arizona. Prior to Arizona, Dr. Hay served as Vice President for Research at the University of Iowa.

She is an international leader in understanding the effects of Angiotensin-(1-7)/Mas receptor pathways to inhibit brain inflammation, protect cognitive function, and prevent and treat Alzheimer’s Disease Related Dementias.

Dr. Hay created the new UA Center for Applied NanoBioscience and Medicine. The center's goals are to develop novel molecular-based diagnostic tests that can be used by individuals and public health systems to facilitate personalized medicine.

Her research current efforts are focused are the development of novel neuroprotective peptide therapies for treatment of cognitive dysfunction in patients with cardiovascular disease. Dr. Hay’s recent discovery of a novel neuroprotective peptide has led to the creation of a new biotechnology company, ProNeurogen, Inc, where she currently serves as President and co-founder.

ProNeurogen is a preclinical and clinical stage biopharmaceutical company developing novel peptide-based therapeutics to treat vascular dementia and cognitive impairment and pain. Dr. Hay and ProNeurogen are collaborating with physicians and scientists at the University of Arizona’s Sarver Heart Center, the Evelyn F. McKnight Brain Institute, BIO5 Institute and Banner Alzheimer’s Institute and the National Institute on Aging to advance these peptides through clinical trials and FDA market approval.

Dr. Hay was a tenured faculty member of the University of Missouri-Columbia from 1996-2005. Prior to Missouri, she was a faculty member in the Department of Physiology at the University of Texas Health Science Center-San Antonio.

Meredith Hay, Ph.D. works effectively with multiple constituencies to communicate the value of the public research land-grant university to community leaders, state legislators, the federal delegations, the Governor’s office, trustees, donors, and the general public. Further, Dr. Hay has extensive experience in working with federal agencies and aligning university research expertise with agency needs.

Education
* B.A. in psychology from the University of Colorado, Denver, 1983
* M.S. in neurobiology from the University Texas at San Antonio, TX, 1987
* Ph.D. in cardiovascular pharmacology from the University of Texas Health Sciences Center, San Antonio., TX, 1990
* Trained as a postdoctoral fellow in the Cardiovascular Center at the University of Iowa College of Medicine and in the Department of Molecular Physiology and Biophysics at Baylor College of Medicine in Houston.

Awards
* National Academy of Inventors, Fellow, 2021
* American Physiological Society, Fellow (FAPS), 2017-present
* American Physiological Society, 1987-Present
* Society for Neuroscience, 1985-
* Federation of American Societies for Experimental Biology, 1987-
* American Heart Association Council for High Blood Pressure Research, 1995-
* American Association for the Advancement of Science, 1995-
* Advisory Board, Department of Psychology, 2015-present
* Center for Innovation in Brain Science Advisory Committee, 2016-present

Selected Grants
* mP.I., M. Hay, NIA UO1, “IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Vascular Dementia”, Support for project period, 2020-20204.
* mPI., M.Hay, NIA R43-Phase 1, “Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment”, 2020-2021
* m-P.I., M. Hay, NIA, R43-Phase 1, “Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)”. 2019-2020.
* P.I., M. Hay (with Sweitzer and Ryan), NHLBI U01 “Evaluation of the Safety and Efficacy of Angiotensin 1-7 to enhance cognitive function in participants undergoing coronary artery bypass graft (CABG) surgery”, Support for project period, 2017-2019.
* Co-I., M. Hay. Arizona Alzheimer’s Consortium, Effects of Ag-(1-7) on Heart Failure Related Dementia” Direct support for project period, 2015-2016.
* P. I. M. Hay., Gooter Foundation Grant, “Effects of Ag-(1-7) on Heart Failure Related Dementia”, Direct support for project period.
* P.I. M. Hay. NHLBI SMARTT Program Support: “Regulatory support for IND submission for therapy to treat CABG related cognitive impairment.” To study regulatory support for IND medication submission for therapy to treat open heart surgery (CABG) related cognitive impairment. Role: PI
* NIH RO1 HL098207, “Neural Control of the Circulation: Sex and Hypertension” P.I.: AK Johnson, Co-I: M. Hay; 2% effort, Direct support for project period, 07/10-06/14

Selected Publications

A. Book Chapters/Reviews
* Books Edited Principles of Sex-Based Physiology, In: Advances in Molecular and Cell Biology, Vol. 34, Elsevier Publishing Company; editors, V. M. Miller, M. Hay, 2004.
* Book Chapters/Proceedings
- Hay, M., Xue, B., and AK Johnson., "The Protective Role of Estrogen and Brain Estrogen Receptors in the Pathogenesis of Hypertension" in Sex Differences in Cardiovascular Physiology and Pathophysiology, Elsevier, June 2019.
- Bowles, D. K. and M. Hay. Cardiovascular Membrane Excitability and the Influence of Sex and Sex Steroids, Principles of Sex-Based Physiology, In: Advances in Molecular and Cell Biology, Vol. 34, Elsevier Publishing Company; editors, V. M. Miller, M. Hay, 2004.
- Hay, M.. Subcellular Mechanisms of Area Postrema Activation. Clin Exp Pharmacol Physiol,28: 551-557, 2001.
- Hay, M., Hoang, C. J. and J. Pamidimukkala. Cellular Mechanisms Regulating Synaptic Vesicle Exocytosis And Endocytosis in Aortic Baroreceptor Neurons. The Annuls, New York Academy of Sciences, Vol 940:119-131, 2001.

B. Selected Refereed Publications
* Hay, M., Ryan, Lee, Huentelman, M., Konhilas, J., Hoyer-Kimura, C., Beach, T. G., Serrano, G., Reiman, E., Blennow, K., Zetterberg, H., and S. Parthasarathy. Serum Neurofilament Light is Elevated in COVID-19 Positive Adults in the ICU and is Associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness., MedRxIv.,doi: https://doi.org/10.1101/2021.04.28.21256277
* Hay M, Barnes C, Huentelman M, Brinton R, Ryan L., Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging. Curr Hypertens Rep. 2020 Sep 3;22(10):80. doi: 10.1007/s11906-020-01090
* Hay, M. Barnes, C., Huentelman, M. , Brinton, R. and L. Ryan. Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging. Current Hypertension Reports. Sep 3;22(10):80. doi: 10.1007/s11906-020-01090-w,. 2020.
* Samuelson LC, Hay M, and J. Pollock , A Year of Challenge and Change., Physiology (Bethesda). Nov 1;35(6):358-360. doi: 10.1152/physiol.00032.202, 2020.
* Talboom JS, Håberg A, De Both MD, Naymik MA, Schrauwen I, Lewis CR, Bertinelli SF, Hammersland C, Fritz MA, Myers AJ, Hay M, Barnes CA, Glisky E, Ryan L, Huentelman MJ. Family history of Alzheimer's disease alters cognition and is modified by medical and genetic factors. Elife. 2019 Jun 18;8. pii: e46179. doi: 10.7554/eLife.46179
* Ryan L, Hay M, Huentelman MJ, Duarte A, Rundek T, Levin B, Soldan A, Pettigrew C, Mehl MR, Barnes CA. Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging. Front Aging Neurosci. 2019 Jun 7;11:128. doi: 10.3389/fnagi.2019.00128
* Hay, M., Polt, R., Heien, M. H., Vanderah, T. W., Largent-Milnes, T. M., Rodgers, K., Falk,T., Bartlett, M., Doyle, K. P. and J. P. Konhilas. A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction. J Pharmacol Exp Ther. Apr;369(1):9-25, 2019.
* Sands JM, Hay M, Brown D. APS: Moving Forward to Aid Our Membership. Physiology (Bethesda). 2018 Nov 1;33(6):370-371
* Hay M, Vanderah TW, Samareh-Jahani F, Constantopoulos E, Uprety AR, Barnes CA, Konhilas J. Cognitive impairment in heart failure: A protective role for angiotensin-(1-7)., Behav Neurosci. 2017 Feb;131(1):99-114.
* Hay M. Sex, the brain and hypertension: brain oestrogen receptors and high blood pressure risk factors. Clin Sci (Lond). 130(1):9-18, 2016.
* Hay M., The Good and the Bad: Immune Cells and Hypertension. Circulation Res. 117(10):830-1, 2015.